Prohibits the use of funds by the Food and Drug Administration (FDA) to process a biologics license application for any biologic product that is, bears, or contains an agent or toxin listed in federal regulations as dangerous to life, property, or the environment and that has been marketed, sold, or distributed to the Islamic Republic of Iran by an entity under investigation for potential violations of the Iran Sanctions Act of 1996.